News
![](/wp/wp-content/themes/gaia/common/images/page_bg_01.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_02.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_03.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_04.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_05.png)
![](/wp/wp-content/themes/gaia/common/images/page_bg_06.png)
Media
Back
Nikkei Biotech ONLINE – GAIA BioMedicine is now developing allogeneic natural killer (NK)-like cell therapy for solid tumors –
Our President & CEO Kazu Kuramori and senior advisor Dr. Yui Harada (Associate professor, Kyushu University), took an interview with Nikkei Biotech: “Our first clinical trial is to be started in 2021